Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages 3269-3279

  Klubo Gwiezdzinska, Joanna ^b,c   Costello Jr , John ^a   Patel, Aneeta ^a   Bauer, Andrew ^a   Jensen, Kirk ^a   Mete, Mihriye ^c   Burman, Kenneth D ^c   Wartofsky, Leonard ^c   Vasko, Vasyl ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; P70S6K PROTEIN; PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BODY MASS; CANCER GROWTH; CANCER SIZE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIFFERENTIATED THYROID CANCER; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REMISSION; RETROSPECTIVE STUDY; TUMOR INVASION;

ADULT; AGED; CELL MOVEMENT; CELL PROLIFERATION; DIABETES MELLITUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MALE; METFORMIN; MIDDLE AGED; OXIDATIVE STRESS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84881524522     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3799     Document Type: Article

References (39)

1. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
3. Al-Saif O, Farrar WB, Bloomston M, Porter K, Ringel MD, Kloos RT. Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2187-2194.
4. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 1996;37:598-605.
5. Lee JJ, Chung JK, Kim SE, et al. Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2008;22:727-734.
6. Klubo-Gwiezdzinska J, Van Nostrand D, Atkins F, et al. Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. J Clin Endocrinol Metab. 2011;96: 3217-3225.
7. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer. 2007;110:1451-1456.
8. Links TP, van Tol KM, Jager PL, et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer. 2005;12:273-280.
9. Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid. 2012;22:884-889.
10. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304-1305.
11. Buchs AE, Silverman BG. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. Metabolism. 2011;60:1379-1385.
12. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol. 2009;27:3271-3273.
13. Bo S, Ciccone G, Rosato R, et al. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab. 2012;14:23-29.
14. El-MirMY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000; 275:223-228.
15. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 9:1092-1099.
16. Shaw RJ. LKB1and AMP-activated protein kinase control ofmTOR signalling and growth. Acta Physiol (Oxf). 2009;196:65-80.
17. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 9:1057-1064.
18. Petrushev B, Tomuleasa C, Soritau O, et al. Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. Exp Oncol. 2012;34:17-24.
19. Rocha GZ, Dias MM, Ropelle ER, et al. Metformin amplifies chemotherapy-inducedAMPKactivation and antitumoral growth. Clin Cancer Res. 2011;17:3993-4005.
20. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011;71:3196-3201.
21. Klubo-Gwiezdzinska J, Jensen K, Costello J, et al. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr Relat Cancer. 2012;19:447-456.
22. Chen G, Xu S, Renko K, Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab. 2012;97:E510-E520.
23. Shonai T, Adachi M, Sakata K, et al. MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells. Cell Death Differ. 2002;9:963-971.
24. Li HF, Kim JS, Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol. 2009;4:43.
25. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48:R31-R43.
26. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer. 2011;11:20.
27. CazzanigaM, Bonanni B, Guerrieri-Gonzaga A, Decensi A. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev. 2009;18:701-705.
28. Liu J, Hou M, Yuan T, et al. Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair. Oncol Rep. 2012;28:1406-1412.
29. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27:3297-3302.
30. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord. 2011;9:69-75.
31. Cappelli C, RotondiM, Pirola I, et al. Thyreotropin levels in diabetic patients on metformin treatment. Eur J Endocrinol. 2012;167:261-265.
32. Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab. 2006;91:225-227.
33. Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 15:166-178.
34. Ben Sahra I, Regazzetti C, Robert G, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 71:4366-4372.
35. Sanli T, Storozhuk Y, Linher-Melville K, et al. Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells: modulation of cellular signals regulating cell cycle and survival. Radiother Oncol. 2012;102:459-465.
36. Zannella VE, Cojocari D, Hilgendorf S, et al. AMPK regulates metabolism and survival in response to ionizing radiation. Radiother Oncol. 2011;99:293-299.
37. Mauceri HJ, Sutton HG, Darga TE, et al. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. Oncol Rep. 2012;27:1625-1629.
38. Lin CI, Whang EE, Donner DB, et al. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res. 2010; 8:1217-1226.
39. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.